Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Key structural features include N14E and V17R substitutions (helix stabilisation), 25P/28P/29P proline substitutions (suppression of beta-sheet propensity and amyloid fibril formation, the primary instability mode of native human amylin), a C-terminal proline-to-tyrosine substitution (P37Y) for calcitonin-receptor activity, and N-terminal C20 fatty-diacid acylation via a gamma-Glu linker
Because fatty liver disease is not just an incidental finding
Active Chemical Compound : Body Protection Compound-157 (BPC-157) Industry Kit Designation : BPC-157 10mg (10mg Total Net Weight per Vial) Purity Threshold : 99.2% Verified via HPLC / Mass Spectrometry Physical State Form : Lyophilized White Powder (Vacuum Sealed Cake) Stabilizing Agent Matrix : Low-moisture Mannitol Excipient Base Regulatory Standing : Strictly for In Vitro and Laboratory Evaluation Only Chemical Profile and Mechanism of Action The BPC-157 peptide formulation consists of a pentadecapan peptide
Binding studies employed tritiated small molecule HGF analogs to map the distribution of HGF/c-Met receptors in the brain, establishing a correlation with known AT4 receptor densities
Drug that shifts brains signaling balance could treat autism A drug that alters the balance of two key chemical messengers in the brain may help treat autism, suggests a proof-of-principle study
US$ 29.32
US$ 20.47
US$ 27.17
US$ 29.28
